Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hybio Pharmaceutical

Request full access

Shenzhen Hybio Pharmaceutical is a high-tech enterprise which engaged in research, development, production, and sales of polypeptide drugs

Shenzhen, ChinaFounded 1998Biotech & Life Sciences

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. is a high-tech enterprise focused on the research, development, and manufacturing of a wide range of peptide products. Established in 1998, Hybio has grown to become one of the largest and most professional peptide pharmaceutical companies in China. The company operates in the pharmaceutical industry, specifically targeting the peptide sector, which involves short chains of amino acids used in various medical treatments. Hybio serves a diverse clientele, including hospitals, research institutions, and pharmaceutical companies, both domestically and internationally.

Hybio's business model revolves around the production and sale of peptide finished dosage products, peptide active pharmaceutical ingredients (APIs), and providing contract research and manufacturing services (CRO/CMO). The company generates revenue through the direct sale of its peptide products and by offering specialized services to other pharmaceutical companies.

Hybio's market presence is bolstered by its comprehensive product range and its commitment to innovation and quality. The company has received numerous accolades, including being listed in Forbes China and winning the Shield Award. Hybio's participation in global events such as the AAPS Annual Meeting and CPHI Worldwide further underscores its prominence in the industry.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2011

Hybio Pharmaceutical in the Shenzhen ecosystem

Live from Dealroom

The Hybio Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Hybio Pharmaceutical on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.